PVI
RNAM

Pura Vida Investments’s Avidity Biosciences RNAM Stock Holding History

Pura Vida Investments’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,506
Closed -$302K – 238
2022
Q3 		$302K Buy
+18,506
New +$354K 0.02% 179

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Pura Vida Investments's RNAM Position: Q4 2022 in Review

Pura Vida Investments sold out of Avidity Biosciences (RNAM) in Q4 2022, closing a stake of 18,506 shares — an estimated $302K sold.

Pura Vida Investments first reported a position in RNAM in Q3 2022 and held it in 1 quarter. The position peaked at $302K in Q3 2022. 148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Pura Vida Investments reported no remaining Avidity Biosciences position as of Q4 2022 after selling out during the quarter.
  • Pura Vida Investments sold 18,506 Avidity Biosciences shares in Q4 2022, an estimated $302K.
  • Pura Vida Investments first reported a position in Avidity Biosciences in Q3 2022 and held it in 1 quarter.
  • Pura Vida Investments's Avidity Biosciences position peaked at $302K in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.